Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre.

Barry D HockKatie S MulhollandPeter GanlyJudith L McKenzieJohn F PearsonSean A MacPherson

Published in: Internal medicine journal (2020)

In the setting of a NZ hospital the increased availability of NA was associated with a significant improvement in both the OS of older patients and the PFS of ASCT patients.

Keyphrases

end stage renal disease
multiple myeloma
ejection fraction
newly diagnosed
chronic kidney disease
healthcare
peritoneal dialysis
patient reported outcomes